Table 1.

Percentage of ¹³C-enrichment and enrichment profiles in selected amino acids in controls and EJ28Luc and LN18 cell lines after treatment with ²¹³Bi-anti-EGFR-MAb.

	EJ28Luc		LN18
	Control	213Bi-anti-EGFR-MAb	Control	213Bi-anti-EGFR-MAb
Alanine
M + 1	0.56% ± 0.04%	0.59% ± 0.04%	0.66% ± 0.02%	0.63% ± 0.03%
M + 2	0.30% ± 0.01%	0.28% ± 0.01%	0.44% ± 0.00%	0.40% ± 0.02%
M + 3	4.09% ± 0.02%	3.58% ± 0.02%***	6.27% ± 0.05%	6.21% ± 0.14%
Aspartate
M + 1	1.79% ± 0.06%	1.53% ± 0.06%**	1.97% ± 0.06%	1.81% ± 0.10%
M + 2	2.12% ± 0.02%	1.78% ± 0.02%***	2.78% ± 0.08%	2.75% ± 0.08%
M + 3	0.98% ± 0.00%	0.82% ± 0.00%***	1.84% ± 0.03%	1.83% ± 0.06%
M + 4	0.13% ± 0.01%	0.10% ± 0.01%*	0.27% ± 0.01%	0.25% ± 0.01%
Glutamate
M + 1	2.27% ± 0.04%	2.08% ± 0.04%**	2.54% ± 0.00%	2.49% ± 0.07%
M + 2	3.22% ± 0.03%	2.88% ± 0.03%***	5.57% ± 0.03%	5.56% ± 0.18%
M + 3	1.01% ± 0.01%	0.95% ± 0.01%**	1.70% ± 0.05%	1.73% ± 0.09%
M + 4	0.52% ± 0.00%	0.48% ± 0.00%***	0.95% ± 0.01%	0.94% ± 0.05%
M + 5	0.15% ± 0.00%	0.14% ± 0.00%***	0.36% ± 0.01%	0.35% ± 0.02%
Glycine
M + 1	0.45% ± 0.04%	0.47% ± 0.04%	0.23% ± 0.03%	0.22% ± 0.03%
M + 2	1.72% ± 0.04%	1.72% ± 0.04%	0.54% ± 0.04%	0.50% ± 0.04%
Proline
M + 1	1.26% ± 0.45%	1.49% ± 0.45%	0.42% ± 0.03%	0.41% ± 0.03%
M + 2	2.47% ± 0.14%	2.30% ± 0.14%	1.24% ± 0.15%	1.33% ± 0.06%
M + 3	0.46% ± 0.03%	0.42% ± 0.03%	0.21% ± 0.02%	0.21% ± 0.00%
M + 4	0.00% ± 0.00%	0.00% ± 0.00%	0.00% ± 0.00%	0.00% ± 0.00%
M + 5	0.00% ± 0.00%	0.00% ± 0.00%	0.00% ± 0.00%	0.00% ± 0.00%
Serine
M + 1	3.24% ± 0.07%	2.76% ± 0.07%**	1.52% ± 0.24%	1.94% ± 0.16%
M + 2	1.32% ± 0.00%	1.19% ± 0.00%***	0.67% ± 0.07%	0.68% ± 0.04%
M + 3	1.45% ± 0.00%	1.18% ± 0.00%***	0.87% ± 0.04%	0.71% ± 0.05%*

*p < 0.05, **p < 0.01, ***p < 0.0001 compared to controls.